CDT Equity Inc. has begun human skin studies with QIMA Life Sciences to test its novel tapinarof combinations for vitiligo, a skin condition affecting up to 2% of the global population. These studies use human skin samples from healthy donors and patients to provide more relevant preclinical data, aiming to improve confidence in clinical success. The global vitiligo drug market is expected to grow significantly, and CDT plans to license these combinations to partners for commercialization. Positive study results will support their licensing efforts backed by patents and AI analysis.
CDT Equity Inc.'s novel tapinarof combinations for vitiligo enter human skin studies as a backdrop to a health sector where 67 of 150 US stocks rose and 75 fell today. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: Canopy Growth Corp (CGC) rose 3.31% to USD 0.61 with a typical hold time of 40 days and 100% buy order activity; Medline Inc. Class A (MDLN) fell 2.93% to USD 39.71 with a 6-day hold; Butterfly Network Inc. Class A (BFLY) gained 2.92% to USD 6.70 with a 15-day hold.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
